Lynavoy (Linerixibat) Wins FDA Approval for Rare Liver Disease After Alfasigma-GSK Licensing Deal

Key Takeaways

• Lynavoy is first FDA‑approved therapy for PBC‑related itch
• Licensing deal gives Alfasigma up to $690 M, $300 M upfront
• Phase III GLISTEN trial showed rapid, sustained itch reduction
• Market now led by Ipsen’s Iqirvo and Gilead’s Livdelzi

Pulse Analysis

Primary biliary cholangitis remains one of the most challenging autoimmune liver disorders, largely because cholestatic pruritus can dominate the patient experience. Up to 89% of PBC sufferers endure relentless itching that disrupts sleep and mental health, and existing treatments have focused on disease progression rather than symptom relief. Lynavoy’s approval marks a watershed moment, offering clinicians a targeted option that directly attenuates the bile‑acid‑driven itch pathway, a first in the United States.

Lynavoy (linerixibat) belongs to the ileal bile acid transporter (IBAT) inhibitor class, reducing intestinal reabsorption of bile acids and thereby lowering circulating pruritogenic mediators. The GLISTEN Phase III trial enrolled patients with moderate‑to‑severe itch and demonstrated statistically significant reductions in itch severity within weeks, sustained through a 24‑week period, with a safety profile mirroring earlier studies. This mechanism‑specific approach validates growing evidence that bile‑acid signaling is central to cholestatic itch, positioning IBAT inhibition as a credible therapeutic strategy beyond PBC, potentially extending to other cholestatic conditions.

Commercially, the GSK‑Alfasigma licensing pact unlocks a revenue stream valued at up to $690 million, featuring a $300 million upfront cash infusion and milestone payments tied to regulatory and sales performance. Alfasigma, fresh from its $800 million acquisition of Intercept Pharmaceuticals, is re‑entering the PBC arena after Ocaliva’s withdrawal, while GSK gains its first liver‑focused product. The approval reshapes a market now dominated by Ipsen’s Iqirvo and Gilead’s Livdelzi, suggesting intensified competition and heightened focus on patient‑centric outcomes in rare liver disease therapeutics.